Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
Scientific Community
Become a Member | Sign in
Home>News>This Article

Geron Issues Statement regarding European Patent Office Decision in WARF Patent Appeal

Published: Friday, November 28, 2008
Last Updated: Wednesday, December 03, 2008
Bookmark and Share
Geron Corporation announced that the Enlarged Board of Appeals of the European Patent Office (EPO) has issued a decision in case G0002/06, which was an appeal by the Wisconsin Alumni Research Foundation (WARF) against the rejection of claims in WARF’s European Patent Application No. 96903521.1.

The claims of the application pertain to the first isolation of human embryonic stem cells (hESCs) by Dr. James Thomson at the University of Wisconsin.

The decision upholds the rejection of WARF’s claims as being impermissible under a rule of the European Patent Convention that prohibits the patenting of inventions which concern “the uses of human embryos for industrial or commercial purposes.”

In reaching its decision, the Enlarged Board of Appeals emphasised the fact that at the time that the priority patent application was filed (in 1995), the only method of obtaining hESCs, as described in the application, required the use of a human embryo. In contrast, following Thomson’s discovery, many hESC lines became widely available through stem cell banks, obviating the need for researchers to culture the cells from embryonic material. Therefore, this decision should not affect patent applications for later-developed hESC technologies, including technologies developed by Geron to enable scalable manufacture of hESCs for therapeutic and drug discovery applications, and their differentiation into a range of functional cell types, such a pancreatic islet cells and cardiomyocytes.

Indeed the EPO’s own commentary on the decision states that the “decision does not concern the general question of human stem cell patentability.” Furthermore the decision does not affect the patentability of hESCs in other jurisdictions, such as the U.S., that do not have similar restrictions on patentable subject matter. Moreover, some European countries, such as the U.K., explicitly permit the patenting of hESCs.

“While this result is not unexpected given the language of the EPC rule, given the narrow basis for the decision, it should have very limited impact on Geron’s ability to protect our hESC technologies in Europe,” said David J. Earp, J.D., Ph.D., Geron’s chief patent counsel and senior vice-president of business development.

“The facts underlying the decision are specific to the WARF patent application and, importantly, the EPO did not rule that hESC technologies in general are not patentable in Europe. We are optimistic that the EPO will now move to allow the backlog of Geron’s European patent applications that have been on hold pending this decision. These patent applications will underpin Geron’s proprietary position in Europe for both therapeutic and drug discovery applications based on hESCs.”

Geron has an extensive portfolio of patents covering hESC technologies, including Geron-owned patents covering technologies developed by Geron scientists, as well as in-licensed patents. Geron’s hESC patent portfolio includes
34 issued U.S. patents, 15 issued U.K patents and approximately 60 issued in other countries, as well as over 220 applications pending worldwide.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Geron Corporation Appoints Karin Eastham to its Board of Directors
Geron Corporation has announced the appointment of Karin Eastham to its board of directors. Ms. Eastham will also serve as chair of the company’s audit committee.
Monday, March 30, 2009
Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
Geron Corporation announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company’s Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury.
Friday, January 23, 2009
Geron Scientists and Collaborators Demonstrate Activity of Pancreatic Islet-like Cells Derived from Human Embryonic Stem Cells in Diabetes
Survival of Diabetic Mice Improved After Transplantation of hESC-derived ILCs.
Tuesday, October 28, 2008
Scientific News
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
ALS Study Reveals Role of RNA-Binding Proteins
The findings are a significant step forward in validating RNA-based therapy as a treatment for ALS.
3D-Printed Heart-On-A-Chip with Integrated Sensors
Researchers have created the first 3D-printed organ-on-a-chip with integrated sensors, paving the way for more complex, customizable devices.
Gene Therapy Going Global with Portable Device
Portable 'gene therapy in a box' could make future cancer and HIV cures affordable in developing countries.
RNA-Binding Proteins Role in ALS Revealed
Researchers describe how damage to RNA-binding protein contributes to ALS, isolating a possible therapeutic target.
Genome Engineering Paves Way For Sickle Cell Cure
Researchers from UC Berkeley have used CRISPR-Cas9 gene editing to fix the mutated gene responsible for sickle cell disease.
Preventing Alzheimer's in Mice
Researchers have prevented the Alzheimer’s development in mice by using a virus delivery system to transport a specific gene into the brain.
Link Between Heart and Blood Cells in Early Development Found
Researchers have identifed a key factor in determining the fate of early undifferentiated cells during development.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Scientists Speed Up Muscle Repair
Researchers discovered genetically modified mice were able to support far more regenerative stem cells, for muscle repair, than previously thought.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos